Stock Analysts

Dow Chemical and Sigma-Aldrich Sign Supply Pact

The Dow Chemical Company ’s ( DOW ) subsidiary – Dow AgroSciences – and Sigma-Aldrich Corporation ( SIAL ) have signed a manufacturing license and supply agreement, under which, Sigma-Aldrich will make zinc finger nuclease (ZFN) reagents for use with EXZACT Precision Technology. The financial terms of the agreement were undisclosed. Per the agreement, Sigma-Aldrich will act as exclusive manufacturer and supplier of ZFN reagents for the platform […]

Stock Analysts

Update on Celsion’s ThermoDox

Pipeline updates are highly awaited events in the pharma/biotech sector as they play an important role in deciding whether or not to invest in a particular company. These updates provide information on experimental drugs and at times give an insight into the commercial potential of the candidate. […]

Stock Analysts

Weyerhaeuser Spilts Off WRECO

Weyerhaeuser Company ( WY ), which had previously announced a split-off decision for its homebuilding and real estate company, WRECO, has started the exchange offer related to the transaction. WRECO will be merged with a subsidiary of TRI Pointe Homes, Inc. ( TPH ), becoming a wholly owned subsidiary of the latter. […]

Stock Analysts

Pfizer, BioRestorative Therapies Ink Deal

Pfizer ( PFE ) and BioRestorative Therapies ( BRTX ) inked a deal for studying human brown adipose tissue and cell lines. The research deal, which is for two years, will permit the companies to jointly conduct a study (Development and Validation of a Human Brown Adipose Cell Model) to characterize further the identity and metabolic operation of these cell lines. Both Pfizer and BioRestorative Therapies can make use of the data from the study. […]

Stock Analysts

Embraer SA Upgraded to Strong Buy

On May 23, Zacks Investment Research upgraded Embraer SA ( ERJ ) to a Zacks Rank #1 (Strong Buy). Why the Upgrade? Embraer SA reported solid result in the first quarter of 2014 on the back of strong performance by both the Defense & Security and Executive Jets segments […]

Stock Analysts

Williams-Sonoma Hits 52-Wk High on Solid Q1

Shares of Williams-Sonoma, Inc. ( WSM ) reached a new 52-week high of $69.49 on May 22 after announcing robust first-quarter fiscal 2014 results and increasing expectations for the year. Shares of the specialty retailer of home products eventually closed at $68.93, yielding a solid year-to-date return of 18.4%. […]

Stock Analysts

Joy Global’s Shareholder Friendly Move

The board of directors of the mining equipment maker Joy Global Inc. ( JOY ) has approved of a 14% hike in the quarterly dividend rate. The new quarterly dividend of the company will be 20 cents per share, up from the previous rate of 17.5 cents. […]

Stock Analysts

Pebblebrook Adds Prescott Hotel in San Francisco

Pebblebrook Hotel Trust ( PEB ) has acquired the Prescott Hotel in San Francisco, CA, for $49 million. The move comes as this hotel real estate investment trust (REIT) gears up to strengthen its presence in the San Francisco market and leverage on the growing fundamentals. […]

FDA Approval

QIAGEN Receives FDA Approval of therascreen KRAS RGQ PCR Kit Paired with Second Colorectal Cancer Drug

QIAGEN Receives FDA Approval of therascreen KRAS RGQ PCR Kit Paired with Second Colorectal Cancer Drug PR Newswire GERMANTOWN, Maryland and HILDEN, Germany, May 23, 2014 GERMANTOWN, Maryland and HILDEN, Germany , May 23, 2014 /PRNewswire/ — Clinically proven companion diagnostic gains U.S. approval to guide use of Amgen’s Vectibix (panitumumab) in treatment of metastatic colorectal cancer FDA approval (PMA) of therascreen KRAS RGQ PCR Kit for Vectibix expands QIAGEN’s leadership in molecular companion diagnostics for personalized healthcare QIAGEN driving the adoption of molecular tests to guide patient treatment decisions with expanding content menu on the QIAsymphony automation platform portfolio QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced that its therascreen KRAS RGQ PCR Kit ( therascreen KRAS test) has received U.S. […]

FDA Approval

FDA Approves First-Line Use of Vectibix (Panitumumab) Plus FOLFOX for Patients with Wild-Type KRAS Metastatic Colorectal Cancer

FDA Approves First-Line Use of Vectibix (Panitumumab) Plus FOLFOX for Patients with Wild-Type KRAS Metastatic Colorectal Cancer Vectibix is the First and Only Biologic to Offer Significant Survival Benefit as a First-Line Treatment with FOLFOX Chemotherapy for Patients with Wild-Type KRAS Metastatic Colorectal Cancer Approval Reinforces Amgen Commitment to Personalized Medicine PR Newswire THOUSAND OAKS, Calif., May 23, 2014 THOUSAND OAKS, Calif. , May 23, 2014 /PRNewswire/ — Amgen (NASDAQ: AMGN) today announced that the U.S. […]

Stock Analysts

Sarepta to Acquire Manufacturing Facility

Sarepta Therapeutics, Inc. ( SRPT ) entered into an agreement to acquire a multifunctional manufacturing facility on 26 acres of land in Massachusetts for $25 million. The deal is expected to close in July this year depending on certain conditions and extensions in the agreement. […]

Stock Analysts

Sanchez Energy Soars on Acquisition

Independent exploration and production (E&P) company Sanchez Energy Corporation ( SN ) spiked close to 9% after the May 21 announcement of the acquisition of Eagle Ford assets in South Texas from Royal Dutch Shell plc ( RDS.A ). The deal at once doubled the company’s holdings in the Eagle Ford shale. […]

Stock Analysts

MGIC Investment: Evenly Poised

On May 21, we issued an updated research report on the MGIC Investment Corp. ( MTG ). The mortgage insurer reported earnings of 15 cents per share in the first quarter of 2014, outpacing the Zacks Consensus Estimate by nearly 67%. […]

Stock Analysts

Royal Bank of Scotland Charged by Lloyds

The Royal Bank of Scotland Group plc ’s ( RBS ) legal hassles aggravates as Lloyds Banking Group plc ( LYG ) gets involved in a class-action lawsuit against the company, according to a report by Reuters . Lloyds Banking Group is set to claim £420 million ($709 million) owing to The Royal Bank of Scotland’s management of manipulated rights issue worth £12 billion. Lloyds Banking Group, the government backed financial institution, is taking legal action through nine of its pensions and investment management subsidiaries including Scottish Widows Plc, Scottish Widows Unit Fund Ltd, Pensions Management Ltd and Clerical Medical Investments Group […]

Stock Analysts

Wage Shadows Looming Large Over Norway

A continuing impasse over the ongoing wage negotiations in Norway threaten its status as a stable energy producer. Norwegian oil unions – representing close to 16,000 employees working for oil companies, drilling operators and catering firms to the offshore sector – are dragging the stand-off in one way or another since the inception of May. […]